Navigation Links
Decision Resources Launches Analogue Tool To Help Pharmaceutical Companies Quickly Assess Market Opportunity
Date:9/29/2010

BURLINGTON, Mass., Sept. 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, announced today that it has launched the Analogue Tool, a dynamic, interactive web-based platform that allows users to search for product analogues based on a range of metrics. The Analogue Tool categorizes a broad range of markets and products to enable users to quickly understand market opportunities and select appropriate product analogues.

Product analogues in Decision Resources' Analogue Tool are based on actual uptake curves from company-reported sales data and are characterized using clinical measures of drug safety, delivery and efficacy along with formulary information from Fingertip Formulary. The easy-to-navigate platform allows users to quickly target the most relevant analogues whether specific product attributes are known, or merely just the market and year in which a product will launch.

"Product analogues are essential for quickly assessing business opportunities," said Decision Resources Director Stephan Gauldie, Ph.D. "By providing an extensive number of product analogues and a range of metrics, Decision Resources is making it easier for business development teams to quickly access relevant data to understand the market opportunity for investigational products, acquisition targets or possible licensing opportunities."

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Fingertip FormularyFingertip Formulary (www.FingertipFormulary.com), the leading provider of access to and insight into formulary data in the United States, offers comprehensive formulary data covering commercial, Medicaid, Medicare and PBM plans, among others. Fingertip Formulary is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision ResourcesDecision Resources, Inc.Lisa Osgood

Christopher Comfort781-993-2606

781-993-2597losgood@dresources.com

ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Business & Decision North America Announces the Successful Go-Live of Microsoft Dynamics AX at DeVilbiss Healthcare
2. Wise Sky Highlights Their Disappointment at Emergents Decision Not to Enter the China Market
3. Decision Resources Competitive Landscape Seminar Series: Biologics and Biosimilars on September 14, 2010 Will Help Pharmaceutical Companies Understand Market Opportunities for Biologics and Biosimilars
4. FDA Issues Assessments of the 510(k) Program and Use of Science in Decision-Making
5. Medco CEO to Present at the Sanford C. Bernstein & Co., LLC 26th Annual Strategic Decisions Conference 2010
6. Abbott Chairman and CEO Miles D. White to Present at Sanford Bernstein Strategic Decisions Conference
7. HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures
8. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
9. Patients, Physicians Rely on ChemoFx(R) to Support Their Cancer Treatment Decisions
10. Kantar Health and ImpactRx Launch CancerMPact Monthly Drugs and Regimens for Oncology Business Decisions
11. Enbrel Will Remain Decision Resources Clinical Gold Standard Through 2018 for the Treatment of Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)...  AllianceRx Walgreens Prime, the combined central specialty pharmacy ... benefit manager Prime Therapeutics LLC (Prime), today officially began ... unveiling of new signage at its headquarters in ... a few other company-owned facilities across the country. This ... of whom will begin to see the AllianceRx Walgreens ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation announce a ... sensors for real-time monitoring of patients with trauma-related and ... focused on disruptive health solutions for rare disorders and ... record and integrate behavioral, cognitive, physiological and contextual data. ... ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills ... specialty vendors and unique items from across the nation, this holiday-themed event will raise ... offered by the VNA. The boutique will be open Saturday, November 4 (10:00 ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the ... today its plans to open a flagship location in Covington, LA at 401 N. ... To Go store next to Office Depot in the Holiday Square shopping center. Its ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... one of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. ... awards program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at ...
Breaking Medicine News(10 mins):